Home

BioM AG is a consultancy and investment company that is independent of the cluster management agency BioM GmbH. Its head office is located at Martinsried in the heart of the biotech cluster.

» mehr

All information on the Munich Biotech Region and the Leading-Edge Cluster m4 - Personalized Medicine and Targeted Therapies. Cluster management is handled by BioM GmbH.

» mehr

The network of Bavarian biotech regions comprises all the research institutions and companies operating in the life science sector and is coordinated by BioM GmbH.

» mehr

  • » 18.12.2014 German Biotech Pieris (Freising near Munich) goes public in USA
    Reverse merger with formerly Marika Inc., Nevada. » more
  • » 21.11.2014 New report: European metropolitan area of Munich is top location for biotechnology and pharmaceutical industries
    According to a ranking of “Genetic Engineering & Biotechnology News, GEN”, March 2014, (www.genengnews.com), the Munich region ranks within the TOP 9–10 of all listed US clusters when looking at employment, public funding and granted patents. » more
  • » 29.10.2014 Biotech Outsourcing Strategies cmc 2015
    For the partnering event focussing on Chemistry/Manufacture/Controls in Munich on June 10-11, 2015, Bavarian biotechs receive a 10% discount via BioM. » more
  • » 23.10.2014 4th Munich Biomarker Conference
    The interdisciplinary programme of the European Networking Event for Personalized Medicine on November 25th-26th, 2014 is now nearly complete. More and more participants now also register to the partnering and submit their profiles. The congress with exhibition and partnering connects researchers and physicians with the biotech and pharma... » more
  • Marlies Sproll, CSO of MorphoSys » 23.10.2014 MorphoSys has now 3 antibodies in phase-3 - with pharma partners
    Roche, Novartis and now Janssen are the 3 big pharma, whose partnering programmes with a specific MOR antibody have already reached the decisive clinical phase 3. » more
  • » 15.10.2014 Made in Munich: Amgen heading for "Bite" approval
    The American biotech giant Amgen has submitted an application to the immunomolecule blinatumomab, a bispecific antibody which was and is developed in Munich. » more